Effects of Inarigivir (SB9200) Therapy on Immune Responses in Patients with Chronic Hepatitis B (CHB)
|
|
- Terence Farmer
- 5 years ago
- Views:
Transcription
1 Effects of (SB9200) Therapy on Immune Responses Patients with Chronic Hepatitis B (CHB) Renae Walsh 1, Rachel Hammond 1, Kathy Jackson 1, Ros Edwards 1, Chelsea Macfarlane 2, Radhakrishnan P. Iyer 2, Man Fung Yuen 3, Henry LY Chan 4, Nezam H. Afdhal 2, Stephen Locarni 1 1 Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia 2 Sprg Bank Pharmaceuticals, Hopkton, MA, United States 3 University of Hong Kong, Hong Kong, Hong Kong 4 Chese University of Hong Kong, Hong Kong, Hong Kong
2 Disclosures Consultg Fees (eg. Advisory Boards) Contract Research (grant) CONFLICT OF INTEREST Stephen A Locarni Clear B Therapeutics Gilead Sciences Inc Arrowhead Research Corp Sprg Bank Pharmaceuticals, Inc. Roche Molecular AusBio Ltd Janssen (J&J) YES YES YES YES YES YES YES YES YES AbbVie
3 CHB Functional Cure (FC) Sustaed, undetectable HBsAg and HBV DNA serum with or without seroconversion (Lok, A et al Hepatol;66:1296) Is lked to improved clical outcome particularly if achieved before 50 years of age (elimated HCC risk, ly reduced chronic liver disease) Is NOT fluenced by current NA drug treatments Is likely fluenced by endogenous immune recovery and an ive anti HBs Is achieved rarely (1 2% per annum) the natural history of CHB There are no approved predictive biomarkers of HBsAg clearance and development There is a need for an immunity marker the defition of FC because of HBV Transmission and/or Reactivation Issues(s)
4 CHB Functional Cure What is the role for HBsAg seroclearance and achievg functional cure? Most patients (> 90%) have or develop co existg durg CHB which is masked by excess HBsAg (Maruyama, T et al J Cl Invest;91:2586) Anti HBs production (B cell function) is not completely hibited or suppressed CHB, but is of low affity and usually directed to a heterologous HBsAg sub type (Zhang, JM et al C.F.D.;44:1161.; Gerlich, WH C.I.D.;44:1170) Hypothesis Indicative of an underlyg/emergg host immune that is adequate or masked (complexed) or both Developed Biomarkers for: HBsAg Epitope Loss or Ga Complexed Anti HBs Assays
5 Assay for HBsAg clearance: Biomarker #1 HBsAg epitope mappg 19plex immunoassay to identify an HBsAg Clearance Profile (CP) HBsAg (viral envelope prote) has highly conformational structure ( a determant) HBsAg profile reported based on epitope display (antigen conformation) and occupancy ( native anti HBs recovery) across the a determant ASSAY HBsAg Epitope Mappg 19 mabs HBsAg clearance profile (CP) HBsAg epitope pressure (reduced recognition) at both loop 1 AND loop 2 epitopes secondary to an antibody that clears fection HBsAg non clearance profile (NCP) change HBsAg epitope profile, OR reduced epitope bdg at only one loop The HBsAg CP is a predictive biomarker for HBsAg clearance, potentially associated with or driven by the selective pressure of an ive Walsh, R et al AASLD (2015; 2016)
6 Clical Cohort A [GS US ]: Validation of Clearance Profile 25 CHB patients (gena) on NA therapy: HBsAg Loss (SL) / FC (n=14) c.f. n Responders (n=11) Development of an HBsAg CP with an outcome of HBsAg loss was also ly correlated to: The level of HBsAg decle (p value to ) An ALT flare / immune (p value 0.017), precedg HBsAg and HBsAg loss Walsh R, et al. AASLD 2015 & 2016
7 Assay for Complexed Anti HBs: Biomarker #2 EIA to detect MASKED (complexed to HBsAg) Standard diagnostic serology detects ONLY free Anti HBs (and free HBsAg) Masked /complexed EIA detects the presence of excess HBsAg Represents underlyg or ongog Potential biomarker for HBV virion and/or HBsAg seroclearance ASSAY Masked Anti HBs Walsh R, et al. EASL 2016 Masked (or complexed) HBsAg/ must be present the tested sample to get reporter bdg (absorbance) Records complete HBsAg clearance, i.e. detects HBsAg the presence of excess maskg/ Masked impacts the defition and confirmation of Functional Cure Reports the detection of TRUE HBsAg clearance vs diagnostic HBsAg clearance
8 Validation of Complexed Anti HBs Cohort A [GS US ]: Walsh R, et al. AASLD 2015 & 2016 Development of masked/complexed may represent: Recovery of the immune Reduction of free HBsAg to crease the ratio of complexed/masked
9 RIG I antiviral function for HBV The RNA sensor RIG I dually functions as an nate sensor and direct antiviral factor for HBV RIG I senses the HBV genotype A, B, and C for the duction of type III IFNs The 5 ε region of HBV pgrna is a key element for the RIG I mediated recognition RIG I counteracts the teraction of HBV P with pgrna to suppress viral replication Type III IFNs are predomantly duced human hepatocytes durg HBV fection is a small molecule ducleotide orally active HBV antiviral Inhibits viral replication: bds RIG I to prevent viral polymerase engagg viral RNA Promotes viral clearance: Activated RIG I duces endogenous IFN production Oral prodrug, active metabolite SB 9000 transported to hepatocytes via OATP1 with 30:1 liver to plasma ratio non specific immune s (preclical or phase1 studies) Sato et al., 2015, Immunity 42,
10 Achieve Trial design Study arms: 20 non cirrhotic HBV subjects per cohort, randomized 4:1 between and placebo Aim of Current Analysis: Cohort 1 (25mg) plus Cohort 2 (50mg) [Low Dose] SB9200, n=30 Placebo, n=8 Assessment of of 12 weeks of SB9200 on the virology and anti HBs antibody s Primary endpots: Other endpots: Safety and antiviral activity at 12 weeks PK, change serum HBV DNA, HBsAg, HBeAg, HBV RNA and HBcrAg from basele to weeks 6, 12, 14, 16 and 24
11 Basele Demographics Cohort 1 and 2 Placebo 25mg HBeAg +ve 25mg HBeAg ve 50mg HBeAg +ve Number Age Gender M:F 6 : 2 5 : 4 3 : 4 9 : 2 5 Basele ALT Basele HBV DNA log Genotype A B C D mg HBeAg ve 3 1 In cohort 2, two patients, one HBeAg +ve, and one HBeAg ve, withdrew at day 1 and day 14 due to patient choice
12 Anti-viral efficacy cohort 1 and 2: Basele to week 12 MEAN Placebo 25mg HBeAg +ve 25mg HBeAg ve 50mg HBeAg +ve 50mg HBeAg ve Basele HBV DNA log Change DNA (BL to week 12) * # 1.05 log 10 Basele HBsAg log Change HBsAg log t-test vs placebo *P < 0.03 # p < $ p < 0.01 & p < 0.01 Basele HBV RNA log $ & Change HBV RNA
13 : CP and Masked Anti HBs Biomarker Analysis #1 HBsAg CP analysis: Biomarker of HBsAg clearance/ [possible functional cure outcome] Study Cohort/Arm CP Detected (to W12) CP Detected (to EOS week 24), Cohort 1 (n=16) 6 (33%) 5 (32%) Placebo, Cohort 1 (n=4) 0 2 (50%), Cohort 2 (n=14) 4 (29%) 5 (36%) Placebo, Cohort 2 (n=4) 1 (25%) 1 (25%) Masked development from W2 [Indicative of underlyg ] Study Cohort/Arm Detected ( W2 to W12) Detected ( W14 to EOS week 24), Cohort 1 (n=16) 2 (11%) 1 (6%) Placebo, Cohort 1 (n=4) 1 (25%) 1 (25%), Cohort 2 (n=14) 7 (50%) 4 (29%) Placebo, Cohort 2 (n=4) 1 (25%) 0 Trend for developg an HBsAg CP and/or masked on vs placebo, but not statistically Dose Response (50mg vs 25mg): HBsAg CP development similar between low dose, but trend for enhanced masked dicative of underlyg activity 50mg cohort vs 25mg
14 Cohort Study arm Masked : Anti HBs and HBV Biomarker Analysis #2 Responses developed to W12 Cohort 1 (25mg), n=20 (n=16) Placebo (n=4) CP Masked 2 (11%) 6 (33%) 1 (17%), HBV DNA 2 (33%), HBV RNA 3 (50%), Masked anti HBs AND HBV DNA 2 (100%), n=2 1 (25%) Cohort 2 (50mg), n=18 Combed Cohorts, n=38 (n=14) Placebo (n=4) (n=30) Placebo (n=8) 7 (50%) 4 (29%) 2 (50%), n=4 4 (100%), n=4 3 (100%), n=3 7 (100%), n=7 1 (25%) 1 (25%) (30%) 10 (33%) 3 (30%), 6 (60%), 6 (67%), 9 (100%), 2 (25%) 1 (12%) Difference: vs placebo
15 Cohort Study arm Masked : Anti HBs and HBV Biomarker Analysis #2 Responses developed to W12 Cohort 1 (25mg), n=20 (n=16) Placebo (n=4) CP Masked 2 (11%) 6 (33%) 1 (17%), HBV DNA 2 (33%), HBV RNA 3 (50%), Masked anti HBs AND HBV DNA 2 (100%), n=2 1 (25%) Cohort 2 (50mg), n=18 (n=14) Placebo (n=4) 7 (50%) 4 (29%) 2 (50%), n=4 4 (100%), n=4 3 (100%), n=3 7 (100%), n=7 1 (25%) 1 (25%) Combed Cohorts, n=38 (n=30) Placebo (n=8) Difference: vs placebo 9 (30%) 10 (33%) 3 (30%), 6 (60%), 6 (67%), 9 (100%), 2 (25%) 1 (12%)
16 Cohort 1 and 2 : Summary Responses developed to W12 Cohort Study arm HBV DNA HBsAg HBeAg HBV RNA (>0.5 log) ALT crease (>0.5 log) HBV DNA AND HBV RNA Masked CP Masked HBV DNA HBV RNA Masked AND HBV DNA Cohort 1 (25mg), n=20 (n=16) 9 (56%) 5 (31%) 1 (11%), 10 (62%) 0 8 (50%) 2 (11%) 6 (33%) 1 (17%), 2 (33%), 3 (50%), 2 (100%), n=2 PL (n=4) (33%), n=3* 1 (25%) 1 (25%) 0 1 (25%) Cohort 2 (50mg), n=18 (n=14) 12 (86%) 1 (7%) 1 (12%), n=8 4 (40%), 1 (7%) 4 (40%), 7 (50%) 4 (29%) 2 (50%), n=4 4 (100%), n=4 3 (100%), n=3 7 (100%), n=7 PL (n=4) 1 (25%) 1 (25%) 1 (50%), n=2 1 (25%) 0 1 (25%) 1 (25%) 1 (25%) All Cohorts n=38 (n=30) 21 (70%) 6 (20%) 2 (12%), n=17 14 (54%), n=26 1 (3%) 12 (46%), n=26 9 (30%) 10 (33%) 3 (30%), 6 (60%), 6 (67%), 9 (100%), PL (n=8) 1 (12%) 1 (12%) 2 (40%), n=5* 2 (25%) 1 (12%) 1 (12%) 2 (25%) 1 (12%) Difference vs placebo 58% pts [p=0.005] 29% pts 34% pts
17 Cohort 1 and 2 : Summary Responses developed to W12 Cohort Study arm HBV DNA HBsAg HBeAg HBV RNA (>0.5 log) ALT crease (>0.5 log) HBV DNA AND HBV RNA Masked CP Masked HBV DNA HBV RNA Masked AND HBV DNA Cohort 1 (25mg), n=20 (n=16) 9 (56%) 5 (31%) 1 (11%), 10 (62%) 0 8 (50%) 2 (11%) 6 (33%) 1 (17%), 2 (33%), 3 (50%), 2 (100%), n=2 PL (n=4) (33%), n=3* 1 (25%) 1 (25%) 0 1 (25%) Cohort 2 (50mg), n=18 (n=14) 12 (86%) 1 (7%) 1 (12%), n=8 4 (40%), 1 (7%) 4 (40%), 7 (50%) 4 (29%) 2 (50%), n=4 4 (100%), n=4 3 (100%), n=3 7 (100%), n=7 PL (n=4) 1 (25%) 1 (25%) 1 (50%), n=2 1 (25%) 0 1 (25%) 1 (25%) 1 (25%) All Cohorts n=38 (n=30) 21 (70%) 6 (20%) 2 (12%), n=17 14 (54%), n=26 1 (3%) 12 (46%), n=26 9 (30%) 10 (33%) 3 (30%), 6 (60%), 6 (67%), 9 (100%), PL (n=8) 1 (12%) 1 (12%) 2 (40%), n=5* 2 (25%) 1 (12%) 1 (12%) 2 (25%) 1 (12%) Difference vs placebo 58% pts [p=0.005] 29% pts 34% pts
18 Cohort 1 and 2 : Summary Responses developed to W12 Cohort Study arm HBV DNA HBsAg HBeAg HBV RNA (>0.5 log) ALT crease (>0.5 log) HBV DNA AND HBV RNA Masked CP Masked HBV DNA HBV RNA Masked AND HBV DNA Cohort 1 (25mg), n=20 (n=16) 9 (56%) 5 (31%) 1 (11%), 10 (62%) 0 8 (50%) 2 (11%) 6 (33%) 1 (17%), 2 (33%), 3 (50%), 2 (100%), n=2 PL (n=4) (33%), n=3* 1 (25%) 1 (25%) 0 1 (25%) Cohort 2 (50mg), n=18 (n=14) 12 (86%) 1 (7%) 1 (12%), n=8 4 (40%), 1 (7%) 4 (40%), 7 (50%) 4 (29%) 2 (50%), n=4 4 (100%), n=4 3 (100%), n=3 7 (100%), n=7 PL (n=4) 1 (25%) 1 (25%) 1 (50%), n=2 1 (25%) 0 1 (25%) 1 (25%) 1 (25%) All Cohorts n=38 (n=30) 21 (70%) 6 (20%) 2 (12%), n=17 14 (54%), n=26 1 (3%) 12 (46%), n=26 9 (30%) 10 (33%) 3 (30%), 6 (60%), 6 (67%), 9 (100%), PL (n=8) 1 (12%) 1 (12%) 2 (40%), n=5* 2 (25%) 1 (12%) 1 (12%) 2 (25%) 1 (12%) Difference vs placebo 58% pts [p=0.005] 29% pts 34% pts
19 Cohort 1 and 2 : Summary Responses developed to W12 Cohort Study arm HBV DNA HBsAg HBeAg HBV RNA (>0.5 log) ALT crease (>0.5 log) HBV DNA AND HBV RNA Masked CP Masked HBV DNA HBV RNA Masked AND HBV DNA Cohort 1 (25mg), n=20 (n=16) 9 (56%) 5 (31%) 1 (11%), 10 (62%) 0 8 (50%) 2 (11%) 6 (33%) 1 (17%), 2 (33%), 3 (50%), 2 (100%), n=2 PL (n=4) (33%), n=3* 1 (25%) 1 (25%) 0 1 (25%) Cohort 2 (50mg), n=18 (n=14) 12 (86%) 1 (7%) 1 (12%), n=8 4 (40%), 1 (7%) 4 (40%), 7 (50%) 4 (29%) 2 (50%), n=4 4 (100%), n=4 3 (100%), n=3 7 (100%), n=7 PL (n=4) 1 (25%) 1 (25%) 1 (50%), n=2 1 (25%) 0 1 (25%) 1 (25%) 1 (25%) All Cohorts n=38 (n=30) 21 (70%) 6 (20%) 2 (12%), n=17 14 (54%), n=26 1 (3%) 12 (46%), n=26 9 (30%) 10 (33%) 3 (30%), 6 (60%), 6 (67%), 9 (100%), PL (n=8) 1 (12%) 1 (12%) 2 (40%), n=5* 2 (25%) 1 (12%) 1 (12%) 2 (25%) 1 (12%) Difference vs placebo 58% pts [p=0.005] 29% pts 34% pts
20 Morphological forms of HBs antigen and number of particles per ml the serum of highly viremic HBV carriers HBV (Dane particles) 10 9 HBV RNA (10 6 ) filaments spheres Kdly provided by Prof W.H. Gerlich
21 Biomarkers and MOA of DAAs EXTRACELLULAR / SERUM HBV Virions (DNA) HBV Virions (RNA) HBsAg plasma membrane CYTOPLASM DSL DNA pgrna HBx RNA subgenomic mrna Fusion transcripts nucleus membrane NUCLEUS RC DNA DSL DNA PF-RC DNA Michromosome cccdna Tu, T et al Viruses; 9(4). pii: E75 Integrated DSL HBV DNA host genome
22 Biomarkers and MOA of DAAs EXTRACELLULAR / SERUM HBV Virions (DNA) HBV Virions (RNA) HBsAg plasma membrane CYTOPLASM DSL DNA pgrna HBx RNA subgenomic mrna Fusion transcripts nucleus membrane NUCLEUS RC DNA DSL DNA PF-RC DNA Michromosome cccdna Tu, T et al Viruses; 9(4). pii: E75 Integrated DSL HBV DNA host genome
23 Biomarkers and MOA of DAAs EXTRACELLULAR / SERUM HBV Virions (DNA) HBV Virions (RNA) HBsAg plasma membrane CYTOPLASM DSL DNA pgrna HBx RNA subgenomic mrna Fusion transcripts nucleus membrane NUCLEUS RC DNA DSL DNA PF-RC DNA Michromosome cccdna Tu, T et al Viruses; 9(4). pii: E75 Integrated DSL HBV DNA host genome
24 Biomarkers and MOA of DAAs CP MASKED
25 Achieve Trial: Conclusions 12 weeks of therapy (low doses) resulted virological reduction both HBV DNA (1.0 log IU/ml) and HBV RNA (~2.0 log IU/ml) but not HBsAg, or HBeAg Effect more enhanced HBeAg ve patients emergence of a Clearance Profile and Complexed Anti HBs over 30% of patients Dose seen markers of s (Clearance Profile and masked ) This dose reflective of both s DAA and RIG I activation which can drive T FH cells formation and antiviral antibody formation (Sprokholt, JK et al PLOS Pathogens;13(11):e ) This study supports further vestigation with higher doses of and combation treatments
SB9200: A Novel and Efficacious RIG-I Agonist for Chronic Hepatitis B: Results from cohort 1 of the ACHIEVE Trial
SB9200: A Novel and Efficacious RIG-I Agonist for Chronic Hepatitis B: Results from cohort 1 of the ACHIEVE Trial Stephen Locarnini 2, Danny Wong 3, Kathy Jackson 2, Renae Walsh 2, Ros Edwards 2, Rachel
More informationInarigivir: A novel RIG-I agonist for chronic hepatitis B
: A novel RIG-I agonist for chronic hepatitis B Stephen Locarnini, Danny Wong, Kathy Jackson, Renae Walsh, Ros Edwards, Rachel Hammond, Carla S. Coffin, Magdy Elkhashab, Susan Greenbloom, Alnoor Ramji,
More informationMF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9
SB 9200 (Inarigivir), an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from cohort 1 of the ACHIEVE Trial MF Yuen 2, CS Coffin 3, M Elkhashab
More informationSlides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.
Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,
More informationUnderstanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development
Understanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious
More informationHBV Novel Therapies Maria Buti MD, PhD
HBV Novel Therapies Maria Buti MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital CONFLICT OF INTEREST I have financial relationships to disclose within the past 12 months relevant
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement
Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer
More informationNew (Virological) Tools for Testing and Monitoring Hepatitis B and C
New (Virological) Tools for Testing and Monitoring Hepatitis B and C Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious Diseases Reference Laboratory, Doherty
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationWhats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen
Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?
More informationDisclosures. Grant: Arrowhead Pharmaceuticals
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen Man-Fung Yuen * 1, Kevin
More information4th International HIV/Viral Hepatitis Co-Infection Meeting
4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
More informationHepatitis B New Therapies
Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth
More informationAre Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationWhy do we need new HBV treatment and what is our definition for cure?
Why do we need new HBV treatment and what is our definition for cure? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University
More informationHepatitis B: is there still a role for interferon?
16 January 2018 Hepatitis B: is there still a role for interferon? Pietro Lampertico Gastroenterology and Hepatology Division Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of Milan
More information6/9/2015. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Director, Schiff Center for Liver Diseases University of Miami
Grant/Research Support: AbbVie, BMS, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen, Discovery Life Sciences, Beckman Coulter, Inc., Siemens Corporation, MedMira Inc., Conatus Eugene R.
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationNew Drug Research for Chronic Hepatitis B Man-Fung Yuen, MD, PhD
New Drug Research for Chronic Hepatitis B Man-Fung Yuen, MD, PhD Department of Medicine. The University of Hong Kong, Queen Mary Hospital, Hong Kong OVERVIEW Emerging Drugs against HBV Direct-acting antiviral
More informationHBV Cure Definition and New Drugs in Development
HBV Cure Definition and New Drugs in Development Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationThe HBV pipeline and what the SIG can offer
The HBV pipeline and what the SIG can offer Current treatments and definition of cure Where can we get to with current therapies? Special interest group possibilities Where are we headed with HBV cure
More informationHCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud
HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationArbutus Biopharma Corporation, Burnaby, Canada.
HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in Positive and Negative Virally Suppressed Patients With Hepatitis B Kosh Agarwal 1, Ed Gane 2, Wendy Cheng
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationRNA Interference: A New Tool in the Toolbox for Treatment of HBV. Discovery On Target Senior Director, Research 25 September 2017
RNA Interference: A New Tool in the Toolbox for Treatment of HBV Amy Lee Discovery On Target Senior Director, Research 25 September 2017 Arbutus Biopharma Boston, MA NASDAQ: ABUS www.arbutusbio.com Chronic
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationNATURAL HISTORY OF HEPATITIS B
NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationSERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca
SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca Louis Jansen 1,2, Andrew Vaillant 3, Karel van Dort 1, Femke Stelma 1,2, Neeltje
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationOccult Hepatitis B Infection: why, who and what to do?
Occult Hepatitis B Infection: why, who and what to do? MF Yuen, MD, PhD Chair of Gastroenterology and Hepatology Department of Medicine The University of Hong Kong Queen Mary Hospital, Hong Kong Who? Different
More informationCurrently status of HBV therapy: efficacy and limitations
9 November 2016 Currently status of HBV therapy: efficacy and limitations Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of
More informationMechanis%c comparison of RNAi therapeu%cs vs. reverse transcriptase inhibitors (NUCs)
Effec%ve Inhibi%on of cccdna derived mrna/viral An%gens and Tolerability with ARC-520 25 th APASL Conference, 2016 Man-Fung Yuen, MD, PhD The University of Hong Kong On behalf of the Heparc-1001 and Heparc-2001
More informationHBV Treatment Pipeline: Prospects for a Cure. Marion Peters, MD UCSF San Francisco, CA
HBV Treatment Pipeline: Prospects for a Cure Marion Peters, MD UCSF San Francisco, CA HBV Control Inflammatory: normalize serum ALT, biopsy Virologic: decrease HBV DNA Immune: seroconversion HBeAg to anti-hbe
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationWhat Would Hepatitis B Cure Look Like?
Epitope Mapping the HBsAg to Identify Biomarkers Associated with HBsAg Loss in a Treatment Naïve Cohort of Genotype A Chronic Hepatitis B (CHB) Patients Receiving Nucleotide Analogue (NA) Therapy: Implications
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationManagement of HBV infection between Specialist and General Practitioners
13 October 2016 Management of HBV infection between Specialist and General Practitioners Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico
More informationby author Novel approaches towards HBV cure
Jörg Petersen Liver Unit IFI Institute at Asklepios Klinik St. Georg University of Hamburg Germany email: petersen@ifi-medizin.de Novel approaches towards HBV cure New horizons in Hepatitis B,D, and E,
More informationHepatitis B Antiviral Drug Development Multi-Marker Screening Assay
Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationVirion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationHepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationALN-HBV. Laura Sepp-Lorenzino November 11, Alnylam Pharmaceuticals, Inc.
ALN-HBV Laura Sepp-Lorenzino November 11, 2016 2016 Alnylam Pharmaceuticals, Inc. 1 N-Acetyl Galactosamine (GalNAc) sirna Conjugates Subcutaneous Investigational RNAi Therapeutics 5 -sense 5 -AS ASGPR
More informationHBV Cure Overview of Viral and Immune Targets
HBV Cure Overview of Viral and Immune Targets Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada October
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationRNAi Therapy for Chronic HBV Infection
RNAi Therapy for Chronic HBV Infection Bill Symonds, PharmD Chief Development Officer October 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking
More informationThe Evolution of sirna Therapeutics Targeting HBV at Arrowhead Pharmaceuticals. Sept 25, 2018
The Evolution of sirna Therapeutics Targeting HBV at Arrowhead Pharmaceuticals Sept 25, 2018 Disclosures I am an employee and shareholder in Arrowhead Pharmaceuticals, Inc. Safe Harbor Statement This presentation
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationHepatitis delta: often forgotten?
15 th Annual Resistance and Antiviral Therapy Meeting Dr Sarah Hughes King s College Hospital, London Thursday 29 September 2011, Royal College of Physicians, London Hepatitis delta: often forgotten? Dr
More informationNuevos tratamientos para la hepatitis B y Delta.
Nuevos tratamientos para la hepatitis B y Delta. Dra. María Buti. Servicio de Hepatología. Hospital Universitario Vall d Hebron. Barcelona. hat does HBV cure mean? Functional Cure Clinical resolution sustained
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationHepatitis B virus infection. Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital
Hepatitis B virus infection Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital Chronic Hepatitis B - are we in the same situation as hepatitis C? Treatment of chronic hepatitis
More informationProperties of HBV. HBV : Structure. Hepatitis B Virus. Partial dsdna and Enveloped : within the envelope we have (HBsAg) on the surface.
Hepatitis B Virus Partial dsdna and Enveloped : within the envelope we have (HBsAg) on the surface. Also we have Nucleic Acid inside (which is partial ds DNA) and the Nucleocapcid protein which is the
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationMulticenter evaluation of the Elecsys HBsAg II quant assay
CVI Accepts, published online ahead of print on 31 August 2011 Clin. Vaccine Immunol. doi:10.1128/cvi.05122-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAlla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )
Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationEndpoints and New Targets for Curing Hepatitis B
Endpoints and New Targets for Curing Hepatitis B Professor Stephen Locarnini WHO Regional Reference Laboratory for Hepatitis B Victorian Infectious Diseases Reference Laboratory, Doherty Institute Melbourne,
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationNew therapeutic perspectives in HBV: when to stop NAs
Liver International ISSN 1478-3223 REVIEW ARTICLE New therapeutic perspectives in HBV: when to stop NAs Cristina Perez-Cameo, Monica Pons and Rafael Esteban Liver Unit, Department of Internal Medicine,
More informationHepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma
Editorial Hepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma Kazunori Kawaguchi, Masao Honda, Shuichi Kaneko Department of Gastroenterology, Kanazawa University
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationShort title: BENEFIT STUDY, STUDY REPORT (ML25614) Synopsis/Abstract
A Multicenter, prospective, Non-Interventional Study Evaluating Response Parameters during and after Therapy with PEGASYS (Peginterferon alfa-2a 40KD) in Subjects with HBeAg positive or HBeAg negative
More informationMedInform. HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders. Original Article
HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders Nina Nikolova, Deian Jelev, Krassimir Antonov, Lyudmila Mateva, Zahariy Krastev. University Hospital St. Ivan Rilski Sofia, Clinic
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationHBV/HCV Eradication. Prof. Jean-Michel Pawlotsky, MD, PhD
HBV/HCV Eradication Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More information